Overview: The verification and validation of medic 2012 - Software V&V Protocols and Documentation - Webinar By GlobalCompliancePanel
Date2012-07-25
Deadline2012-07-25
VenueWilmington, USA - United States
KeywordsSoftware V&V Protocols, Documentation, Risk Management models, process/equipment control,cGMP data / Part 11 applications.
Websitehttp://alturl.com/9umxt
Topics/Call fo Papers
Overview: The verification and validation of medical software is coming under increased scruinty by the U.S. FDA. This webinar will address the use of the FDA, GAMP, 21 CFR Part 11, "Electronic Records"/ "Electronic Signatures", and other applicable industry software validation models, coupled with the ISO 14971 / ICH Q9 Product Risk Management models, to structure, run, and document acceptable software validations.
The FDA and other regulatory agencies have stated that software validation can only be accomplished effectively if "risk-based". How can this be done in the "real world". This webinar will address software that is:
As-Product
In-Product
Process and/or In Production and Test Equipment
The Quality System.
A manufacturer is responsible to identify these requirements and implement them into an effective software V&V process.
Why should you attend: Software has become pervasive in medical devices themselves, and in the controlling, running and monitoring of medical product processes, whether they be in the pharmaceutical, medical device, biologics or dietary supplements industries. Software is being developed for medical imaging, and even though control of computer for individuals having disabilities restricting hand or eye movement / coordination. The U.S. FDA rightly recognizes that virtually all software quality problems occur in the design, testing and validation phases, since replication of software is relatively defect-free. Regulatory auditors are more comfortable with delving into software issues. Recent problems in unrelated industries show the dangers of neglecting thorough, and risk based, software verification and validation activities. Effective and real world software V&V is even more important in today’s resource constrained industrial environment. This discussion will focus on a preferred U.S. FDA documentation "model" in various applications, including ERP, in-device, as-device, process/equipment control, and cGMP data / Part 11 applications.
Areas Covered in the Session:
Verification or Validation -- FDA Expectations
The Project Validation Plan
An FDA-accepted Documentation "Model"
Product and Process / Test / Facilities / Equipment Software V&V
When and How to Use DQ, IQ, OQ, PQ (or their equivalents)
GAMP / Other Considerations
The FDA's 11 Key V&V Documentation Elements
"White Box" and "Black Box" Validations
Who Will Benefit:
Senior management in Drugs, Devices, Biologics, Dietary Supplements
QA / RA
Software development, programming, documentation, testing teams
R&D
Engineering
Production
Operations
Consultants; others tasked with product, process, electronic records software V&V responsibilities
John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.
Price List:
Live : $245.00
Corporate live : $495.00
Recorded : $295.00
Phone: 800-447-9407
Fax: 302-288-6884
webinars-AT-globalcompliancepanel.com
http://www.globalcompliancepanel.com
http://alturl.com/9umxt
The FDA and other regulatory agencies have stated that software validation can only be accomplished effectively if "risk-based". How can this be done in the "real world". This webinar will address software that is:
As-Product
In-Product
Process and/or In Production and Test Equipment
The Quality System.
A manufacturer is responsible to identify these requirements and implement them into an effective software V&V process.
Why should you attend: Software has become pervasive in medical devices themselves, and in the controlling, running and monitoring of medical product processes, whether they be in the pharmaceutical, medical device, biologics or dietary supplements industries. Software is being developed for medical imaging, and even though control of computer for individuals having disabilities restricting hand or eye movement / coordination. The U.S. FDA rightly recognizes that virtually all software quality problems occur in the design, testing and validation phases, since replication of software is relatively defect-free. Regulatory auditors are more comfortable with delving into software issues. Recent problems in unrelated industries show the dangers of neglecting thorough, and risk based, software verification and validation activities. Effective and real world software V&V is even more important in today’s resource constrained industrial environment. This discussion will focus on a preferred U.S. FDA documentation "model" in various applications, including ERP, in-device, as-device, process/equipment control, and cGMP data / Part 11 applications.
Areas Covered in the Session:
Verification or Validation -- FDA Expectations
The Project Validation Plan
An FDA-accepted Documentation "Model"
Product and Process / Test / Facilities / Equipment Software V&V
When and How to Use DQ, IQ, OQ, PQ (or their equivalents)
GAMP / Other Considerations
The FDA's 11 Key V&V Documentation Elements
"White Box" and "Black Box" Validations
Who Will Benefit:
Senior management in Drugs, Devices, Biologics, Dietary Supplements
QA / RA
Software development, programming, documentation, testing teams
R&D
Engineering
Production
Operations
Consultants; others tasked with product, process, electronic records software V&V responsibilities
John E. Lincoln is a medical device and regulatory affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management, U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and described in peer-reviewed technical articles, and workshops, world wide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions, risk management per ISO 14971, and projects; with over 28 years of experience in the FDA-regulated medical products industry - working with start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, Tyco/Mallinckrodt. He is a graduate of UCLA.
Price List:
Live : $245.00
Corporate live : $495.00
Recorded : $295.00
Phone: 800-447-9407
Fax: 302-288-6884
webinars-AT-globalcompliancepanel.com
http://www.globalcompliancepanel.com
http://alturl.com/9umxt
Other CFPs
- Auditing an Active Pharmaceutical Ingredient (API) Contract Manufacturing Organization (CMO)- Webinar By GlobalCompliancePanel
- Avoiding Statistical Pitfalls during Method Validation - Webinar By GlobalCompliancePanel
- The FDA Inspection Process: From SOP to 483 - Webinar By GlobalCompliancePanel
- IEC 62304 for Medical Device Software Development: Steps to Compliance - Webinar By GlobalCompliancePanel
- How to Prepare for a Tag Along Audit of CFR 21 Part 11 - Webinar By GlobalCompliancePanel
Last modified: 2012-06-28 13:33:27